GlassScriptPhysician profile
Daniel S Brooks
NPI 1114536547
$795.26
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $755 · 2022: $23.55 · 2024: $16.93.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $16.93.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $16.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $183.29 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $122.70 | 2021-2022 | |
| Abbvie INC. | $106.68 | 2021 | |
| Novo Nordisk INC | $98.73 | 2021 | |
| Lilly USA, LLC | $60.62 | 2021 | |
| Nestle Healthcare Nutrition INC. | $58.78 | 2021 | |
| Vanda Pharmaceuticals INC. | $29.85 | 2021 | |
| Organon LLC | $19.86 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $19.65 | 2021 | |
| Pfizer INC. | $18.99 | 2021 | |
| Livanova USA, INC. | $18.50 | 2021 | |
| Tempus Ai, INC | $16.93 | 2024 | |
| Biohaven Pharmaceuticals, INC. | $13.99 | 2021 | |
| Indivior INC. | $13.95 | 2021 | |
| Astellas Pharma US INC | $12.74 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Brooks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.